"RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma Antagonists and Agonists"
Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter.
The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concerns for novel RORgamma modulators were identified.
Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.
The report provides an understanding of:
- The target RORgamma
- Clinical and non-clinical target validation
- Clinical lead and up-side indications
- Drug discovery strategies and technologies
- Commercial value of drug discovery collaborations
- R&D timelines from start of screening to first-in-human studies
- Competitive landscape of RORgamma antagonists
- Agonists of RORgamma for cancer
- Profiles of unpartnered technology companies and lead projects
- R&D Partnerships and their discovery approaches and lead molecules
- Unpartnered pharmaceutical companies and their programs
Table of Contents
2) Executive Summary
3) Target Background
4) Target validation
5) Drug Discover Approaches & Technologies
6) Competitive Landscape of RORgamma Modulators
7) Corporate Stakeholders
Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists
Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models
Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models
Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models
Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models
Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models
Table 6: Overview of Partnership Agreements for RORgamma Modulators
Table 7: Special Collaborations for Discovery of RORgamma Antagonists
Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators
Table 9: R&D Timeline for Discovery of RORgamma Antagonists in Partnership Programs
Table 10: Technologies for Discovery of RORgamma Antagonists
Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development
Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies
Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical R&D
Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs
Table 15: RORgamma Agonists Discovery & Development Programs
Table 16: Technology and Pharma Companies with RORgamma Modulator R&D
Make an enquiry before buying this Report
Please fill the enquiry form below.
Small molecule kinase inhibitors are categorized as enzyme inhibitor that inhibits the mechanism of action of protein kinases. Protein kinases are the enzymes which add phosphate group to a protein or any other organic molecule. Phosphate group posses the capability of inhibiting the functioning of a protein. In a protein, phosphate group is added to the different amino acids such as threonine, serine or tyrosine amino acid for inhibition of prot...
Duodenal ulcer, also called as peptic ulcer is a defect in the lining of the small intestine, an area called duodenum. The lining which protects the small intestine is resistant against the acid which is produced in our stomach. If the protecting line fails to protect the intestine or does not work properly against the acid it results in an ulcer. A causative microorganism for duodenal ulcer is helicobacter pylori, a gram-negative, microaerophili...
Cyclospora cayetanensis, a single-celled coccidian parasitic pathogen, causes intestinal infection resulting in diarrhea. In medical terminology, this diarrheal infection is referred as cyclospora infection (cyclosporiasis).This infection is usually transmitted through feces and ingestion of food and water contaminated with sporulated oocysts. Cyclosporadiagnostic testing is not a routine laboratory test, and is carried upon specific requests fro...